Compare 8x8 Inc (EGHT) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
8x8 Inc vs IDEXX Laboratories, Inc. — how do they compare? 8x8 Inc trades at $2.1 (market cap $311.98M), while IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 129.6× 8x8 Inc's market cap, and 8x8 Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold 8x8 Inc for 16 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| EGHT | IDXX | |
|---|---|---|
Market Cap | $311.98M | $40.43B |
Volume | 1,639,086 | 692,164 |
Sector | Technology | Health |
52-Week High | $2.76 | $766.68 |
52-Week Low | $1.59 | $504.70 |
Typical Hold Time | 16 Days | 46 Days |
Enterprise Value | $578.90M | $41.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EGHT trades at $2.11, down 1.4% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $27.21 million in 2025 despite revenue of $715.07 million, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights cost-saving wins for clients and AI product growth, with a consensus analyst price target of $19.77 suggesting significant upside potential from current levels.
The outlook hinges on the company's ability to translate top-line growth into sustained profitability. While valuation multiples like a P/S of 0.42 appear attractive, a high P/E of 72 and substantial long-term debt of $338.37 million present risks. The primary opportunity is execution on its financial model to achieve positive net income, as projected for 2026.
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About 8x8 Inc
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
